ArQule, Inc., a clinical-stage biotechnology company, researches and develops therapeutics for the treatment of cancer and rare diseases. Its lead product candidate is tivantinib, a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer and non-small cell lung cancer; Phase II clinical trial for the treatment of mesothelioma and kidney cancer; and Phase I clinical trial for the treatment of pediatric tumors, as well as has completed Phase II clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products in Phase Ib clinical trials include ARQ 092, an inhibitor of the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family for patients with cholangiocarcinoma and adrenocortical tumors, as well as with FGFR translocations, amplification, and mutations; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is used as a promoter of NQ01-mediated programmed cancer cell necrosis. Its pre-clinical development program also includes ARQ 751, a next-generation inhibitor of AKT. ArQule, Inc. has partnership agreement with Daiichi Sankyo Co., Ltd. to conduct research, clinical trials, and the commercialization of tivantinib for human cancer indications in the United States, Europe, South America, and internationally; and Kyowa Hakko Kirin Co., Ltd. to develop and commercialize tivantinib in Japan and parts of Asia. The company has collaboration agreement with the National Human Genome Research Institute of the NIH for a clinical trial investigating on ARQ 092, which is used for the treatment of Proteus syndrome. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.